If you have been reading about Enkephalinase and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-06-17. Numbers and descriptions here follow the published literature rather than marketing material.
Naming conventions place Selank in the same research family as Semax, another Russian-developed peptide investigated for cognitive effects. The two compounds share a lineage but differ in sequence and in the biological systems proposed as their targets. Semax descends from ACTH fragments, whereas Selank descends from tuftsin. Publications sometimes identify Selank by its full peptide sequence or by laboratory codes rather than one uniform trade name. Because replication outside Russia is limited, reports on its properties are best read alongside the study design and the purity of the material tested.
Selank is a synthetic heptapeptide developed in Russia during the 1990s. Researchers at the Institute of Molecular Genetics of the Russian Academy of Sciences designed it as a stabilized analog of tuftsin, a naturally occurring immunomodulatory tetrapeptide. The compound has been studied primarily for its reported anxiolytic and nootropic effects. It remains largely unknown in Western pharmacology and is not approved as a medicine by major regulators such as the FDA or the EMA.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic heptapeptide | Stabilized analog of tuftsin |
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Single-letter form: TKPRPGP |
| Molecular formula | C33H57N11O9 | Monoisotopic mass about 751.9 Da |
| Appearance | White to off-white powder | Typically supplied as lyophilized solid |
| Solubility | Freely soluble in water | Also soluble in common polar solvents |
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
The compound was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences during the 1980s and 1990s. The stated design goal was to retain the immunomodulatory and central nervous system activity attributed to tuftsin while improving resistance to enzymatic breakdown. Adding a proline-rich tail to the short parent peptide was a deliberate strategy, because proline residues restrict the conformations available to many peptidases. The same laboratory produced Semax, an ACTH fragment analog, and both compounds were developed in parallel as short, enzymatically stabilized peptides intended for intranasal use.
Selank is not a naturally occurring peptide and has no known endogenous counterpart in human physiology. Russian-language sources frequently call it TP-7, while English-language sources use the name Selank almost exclusively. Database indexing is uneven, partly because early reports appeared in regional journals that are not widely cataloged. Some summaries describe the material as a tuftsin analog and others as a synthetic heptapeptide; the labels overlap rather than conflict. Citing the primary sequence resolves ambiguity more reliably than the research or trade name alone.
Published clinical evidence is limited. Most controlled trials were conducted in Russia, enrolled modest numbers of participants, and appeared in Russian-language journals, which restricts independent verification. Reported outcomes include lower anxiety scores, improved attention and memory measures, and changes in fatigue ratings. Reviews written in English note methodological limitations such as small samples and inconsistent endpoints. Whether the compound produces clinically meaningful benefit relative to established anxiolytics is therefore an open question rather than an established finding.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a structural analogue of tuftsin, a naturally occurring tetrapeptide fragment of the immunoglobulin heavy chain. The added Pro-Gly-Pro tail was intended to slow enzymatic degradation and extend biological activity. In Russia it is registered as an anxiolytic nasal preparation, while regulators elsewhere have not approved it for clinical use.
The compound has a calculated molecular weight near 751.9 daltons and carries a net positive charge at physiological pH because of its arginine residue. It dissolves freely in water and in common aqueous buffers, and typically appears as a white or off-white lyophilized powder. The amide backbone makes the molecule susceptible to peptidases, which limits oral use and favors intranasal or parenteral routes. Nomenclature in the literature varies: the substance is also described by the sequence abbreviation TP-7 and by a Russian trade designation.
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
The pharmacodynamics of spironolactone are characterized by high antimineralocorticoid activity, moderate antiandrogenic activity, and weak steroidogenesis inhibition, among other more minor activities. Spironolactone is a prodrug, so most of its actions are actually mediated by its various active metabolites. The major active forms of spironolactone are 7α-thiomethylspironolactone (7α-TMS) and canrenone (7α-desthioacetyl-δ6-spironolactone). Spironolactone is a potent antimineralocorticoid. That is, it is an antagonist of the mineralocorticoid receptor (MR), the biological target of mineralocorticoids like aldosterone and 11-deoxycorticosterone. By blocking the MR, spironolactone inhibits the effects of mineralocorticoids in the body. The antimineralocorticoid activity of spironolactone is responsible for its therapeutic efficacy in the treatment of edema, high blood pressure, heart failure, hyperaldosteronism, and ascites due to cirrhosis. It is also responsible for many of the side effects of spironolactone, such as urinary frequency, dehydration, hyponatremia, low blood pressure, fatigue, dizziness, metabolic acidosis, decreased kidney function, and its risk of hyperkalemia. Due to the antimineralocorticoid activity of spironolactone, levels of aldosterone are significantly increased by the medication, probably reflecting an attempt of the body to maintain homeostasis. Spironolactone is a moderate antiandrogen. That is, it is an antagonist of the androgen receptor (AR), the biological target of androgens like testosterone and dihydrotestosterone (DHT).
The head of the Wagner Group, Yevgeny Prigozhin, said that he would withdraw his troops from Bakhmut after Russia's Victory Day on 10 May because of ammunition shortages, blaming the Russian military establishment. However, two days later he said he had "received a combat order" and had been promised all ammunition and weapons needed. Russia ordered a partial evacuation of civilians from 18 settlements of Zaporizhzhia Oblast near the Zaporizhzhia Nuclear Power Plant, including Enerhodar, citing increased shelling by the Ukrainian military. A Polish border guard aircraft on patrol for the European Union's border agency Frontex figured in a near-collision with a Russian Su-35 fighter jet in international waters over the Black Sea near Romania. A Polish official said that the Russian jet carried out "aggressive and dangerous manoeuvres" approaching the Polish aircraft without keeping a secure distance, leading to turbulence, loss of altitude and a temporary loss of control of the plane by the crew. Belarus implemented border controls with Russia for the first time since 1995, in what Foreign Minister Sergei Aleinik later said was part of efforts to avoid the entry of third-country nationals into the country but was seen by human rights organizations as an attempt to stem the escape of Russian dissidents and draft evaders.
The public entity was called Fisher Scientific International Inc., and based in Hampton, New Hampshire. Fisher Scientific Company remained in Pittsburgh as an operating subsidiary. In 1992, Fisher facilities were ISO-9000 certified. In the 1990s, Fisher, with partner Intertech Corporation of Atkinson, New Hampshire, set up a pharmaceutical testing and certification lab in Moscow, Russia, to serve with the Russian Federation's Ministry of Health and Medical Industry needs. Fisher acquired Eastman Kodak Company's organic-chemicals business and Janssen Chimica, forming Acros Organics. In August 2004, the company merged with Apogent Technologies Inc., a company engaged primarily in the manufacture and sale of laboratory products in the United States and other countries. In May 2006, Fisher Scientific and Thermo Electron announced that they would merge in a tax-free, stock-for-stock exchange. The merger closed on November 9, 2006, and the merged company is now called Thermo Fisher Scientific. The merger was valued at $12.8 billion.
=== Research (US) === In 2007 an ABC news report said excitement over research into salvia "could vanish overnight if the federal government criminalized the sale or possession of salvia, as the Drug Enforcement Agency [sic] is considering doing right now." Scientists worry that such legislation would restrict further work.
Sources: en.wikipedia.org
Mergny and Lacroix determined that the addition of a bulky methyl group had a destabilizing effect on the i-motif formation when they compared phosphorothioate, the natural phosphodiester, methylphosphonate, and peptide linkages and determined that only phosphodiester and phosphorothioate oligodeoxynucleotides were capable of forming stable i-motifs.
== Natural occurrence == The acid is found in Centella asiatica (Gotu Kola). Other sources include Centella cordifolia and Hydrocotyle umbellata. The compound is closely related to Asiatic acid and is known for its various pharmacological properties, including anti-inflammatory, wound-healing, anti-oxidant, and neuroprotective effects. It is often studied alongside other bioactive compounds from Centella asiatica.
Many jurisdictions require operators be certified or licensed to work with chainsaws. Injury can also result if the chain breaks during operation due to poor maintenance or attempting to cut inappropriate materials. Gasoline-powered chainsaws expose operators to harmful carbon monoxide gas, especially indoors or in partially enclosed outdoor areas. Drop starting, or turning on a chainsaw by dropping it with one hand while pulling the starting cord with the other, is a safety violation in most states in the U.S. Keeping both hands on the saw for stability is essential for safe chainsaw use. Safe and effective chainsaw and crosscut use on federally administered public lands within the United States has been codified since 2016 in the Final Directive for National Saw Program issued by the United States Forest Service, which specifies the training, testing, and certification process for employees and unpaid volunteers who operate chainsaws within public lands.
== Structure == The R1 plasmid belongs to the IncFII plasmid group. The Inc plasmid group stands for incompatibility, and plasmids are classified into this group when two plasmids can't steadily propagate in the same host. The major incompatibility group involved in resistance and virulence gene transfer is the IncF group. Since R1 is an IncFII plasmid, that means it carries the FII replicon. This plasmid subtype often carries blaCTX-M genes.
== History == August Troendle founded Medpace in Cincinnati, Ohio, in 1992 as Medical Research Services. Troendle first became interested in the CRO sector after working in both the regulatory and pharmaceutical area. He began his career as a reviewer with the FDA, specializing in the development of lipid lowering therapies to treat high cholesterol. With a team of industry physicians, Jonathan Issacsohn and Evan Stein completed many early studies while at Medpace and Medpace Reference Laboratories on the use of statin therapies for the treatment of hypercholesterolemia. Another Medpace physician, David Orloff was regarded as an industry opinion leader in the study of metabolic diseases – most specifically diabetes and obesity. Troendle was honored for his work as a Medpace founder in 2012 by the Cincinnati Chamber of Commerce. Medpace completed construction on a new campus in 2012 in Madisonville, a neighborhood on the eastern side of Cincinnati. The project encompassed revitalizing an urban brownfield site formerly occupied by NuTone, and creating a state of the art LEED (Leadership in Energy and Environmental Design) certified campus. In 2022, Medpace announced a $150 million capital investment to expand its headquarters in Cincinnati, Ohio, adding an estimated expansion of 1,500 new jobs. Medpace expanded internationally through several acquisitions between 2007 and 2012. It acquired the Czech Republic contract research organization Monax in 2007, followed by Switzerland-based PharmaBrains AG in 2009.
Sources: en.wikipedia.org
== Clinical potential == As of 2013, bottromycin has not been approved for any clinical applications, nor has it been tested in humans. The in vivo stability of bottromycin must be improved before it can be considered as a drug candidate. Work by Kobayashi and colleagues has already begun to address this issue, but more work may be in progress. The need to find new antibiotics to combat antibiotic resistance means that biologic and synthetic interest in bottromycin will likely continue. A combination of biologic and synthetic techniques may yield both an efficacious and stable bottromycin analog for development as a potential drug candidate.
Integrin alpha-1 also CD49a is an integrin alpha subunit encoded in humans by the gene ITGA1. It makes up half of the α1β1 integrin duplex. Though CD49a can bind a number of ligands including collagen IV, collagen I, and others. CD49a has been implicated as a marker of tissue resident memory T cells, where it may be coexpressed with other markers CD103 and CD69. It has been shown to affect the motility of T cells.
=== Blood and nerve supply === Blood is supplied to the vagina mainly via the vaginal artery, which emerges from a branch of the internal iliac artery or the uterine artery. The vaginal arteries anastamose (are joined) along the side of the vagina with the cervical branch of the uterine artery; this forms the azygos artery, which lies on the midline of the anterior and posterior vagina. Other arteries which supply the vagina include the middle rectal artery and the internal pudendal artery, all branches of the internal iliac artery. Three groups of lymphatic vessels accompany these arteries; the upper group accompanies the vaginal branches of the uterine artery; a middle group accompanies the vaginal arteries; and the lower group, draining lymph from the area outside the hymen, drain to the inguinal lymph nodes. Ninety-five percent of the lymphatic channels of the vagina are within 3 mm of the surface of the vagina. Two main veins drain blood from the vagina, one on the left and one on the right. These form a network of smaller veins, the vaginal venous plexus, on the sides of the vagina, connecting with similar venous plexuses of the uterus, bladder, and rectum. These ultimately drain into the internal iliac veins. The nerve supply of the upper vagina is provided by the sympathetic and parasympathetic areas of the pelvic plexus. The lower vagina is supplied by the pudendal nerve.
=== Hybrid scaffolds === A hybrid scaffold is a skin substitute based on a combination of synthetic and natural materials. Examples of hybrid scaffolds are HYAFF and Laserskin. These hybrid scaffolds have been shown to have good in-vitro and in-vivo biocompatibilities and their biodegradability is controllable.
Sources: en.wikipedia.org
Selank is a synthetic heptapeptide designed as a stabilized analog of the natural tetrapeptide tuftsin. It has been investigated mainly for anxiolytic and cognitive effects. It is not an approved pharmaceutical in most countries.
It was developed in Russia, at the Institute of Molecular Genetics of the Russian Academy of Sciences, during the 1990s. Most published research originates from Russian institutions. Independent international replication remains limited.
Tuftsin is a natural tetrapeptide with the sequence Thr-Lys-Pro-Arg that participates in immune signaling. Selank extends that sequence with Pro-Gly-Pro at the C-terminus. The added residues are linked to greater resistance to enzymatic breakdown.
The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, commonly written as TKPRPGP. It shares the first four residues with tuftsin and carries three prolines in the chain. The proline-rich tail is the main structural feature that separates it from the parent tetrapeptide.